Eli Lilly and Company (NYSE:LLY) Shares Down 3.2%

Shares of Eli Lilly and Company (NYSE:LLY) dropped 3.2% during trading on Friday . The company traded as low as $731.31 and last traded at $731.95. Approximately 1,623,504 shares were traded during trading, a decline of 47% from the average daily volume of 3,050,417 shares. The stock had previously closed at $755.91.

Wall Street Analyst Weigh In

LLY has been the topic of several research analyst reports. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Barclays boosted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research note on Wednesday, February 21st. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Trading Down 2.8 %

The firm’s 50-day simple moving average is $761.06 and its 200 day simple moving average is $671.38. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The firm has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the firm earned $1.62 EPS. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. Equities analysts expect that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently bought and sold shares of the company. Lipe & Dalton bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. grew its stake in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the third quarter valued at $27,000. Activest Wealth Management acquired a new position in Eli Lilly and Company during the 1st quarter worth about $39,000. Finally, Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $29,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.